DECLARATION OF EMERGENCY

Department of Health and Hospitals Board of Pharmacy

Compounding for Prescriber's Use (LAC 46:LIII.Chapter 25)

The Louisiana Board of Pharmacy is exercising the emergency provisions of the Administrative Procedure Act, specifically at R.S. 49:953.B, to repeal certain portions of its rules permitting pharmacists to compound medications intended for administration by practitioners without the necessity of a patient-specific prescription.

The statutory definition of *compounding* at La. R.S. 37:1164(5) embodies three concepts—the necessity of a patient-specific prescription issued in the context and course of a legitimate physician-patient relationship, the inclusion of anticipatory preparation based on routine prescribing patterns, and the exclusion of preparation of copies of commercially available products. There is no statutory authority for the compounding of medications in the absence of a patient-specific prescription. The administrative code currently contains provisions for the preparation and labeling of practitioner administered compounds without the necessity of a patient-specific prescription.

The board has taken note of the recent tragedies associated with fungal meningitis traced to a compounding pharmacy in Massachusetts. That pharmacy was licensed to do business in Louisiana, although none of the cases to date have been located within the state. Further, the Board has learned there are other similar types of pharmacies operating across the country that are licensed to do business in Louisiana. Some of these pharmacies specialize in the large-scale preparation of practitioner administered compounds as opposed to compounding medications pursuant to patient-specific prescriptions. Further, the Board has recently learned that other state boards of pharmacy may have resource limitations that restrict their ability to inspect such facilities on a sufficiently regular basis.

The preparation of compounds in the absence of a patient-specific prescription is construed as manufacturing as opposed to compounding. Compounding by pharmacies is regulated by the Board. Manufacturing is regulated by the federal Food and Drug Administration (FDA). In an abundance of caution for the health, safety and welfare of Louisiana citizens, the Board seeks to repeal the rule which allows the compounding of preparations without the necessity of a patient-specific prescription. The business entity that wishes to continue the preparation of such products will be able to apply for a manufacturer's registration from the federal Food and Drug Administration and then continue their same activities.

The board has determined this emergency rule is necessary to prevent imminent peril to the public health, safety, and welfare. The declaration of emergency is effective December 13, 2012, and shall remain in effect for the maximum time period allowed under the Administrative Procedure Act or until adoption of the final rule, whichever shall first occur. In recognition of the necessity for practitioners to develop alternative business procedures to acquire needed medications for their patients, the Board has instructed its compliance officers to delay their assessment

of compounding pharmacies for compliance with this emergency rule until January 14, 2013.

Title 46

Professional and Occupational Standards Part LIII.PharmacistsChapter 25. Prescriptions, Drugs, and Devices

Subchapter C. Compounding of Drugs §2533. Definitions

A. As used in this Subchapter, the following terms shall have the meaning ascribed to them in this Section.

Practitioner Administered Compounds—Repealed.

AUTHORITY NOTE: Promulgated in accordance with R.S. 37:1182.

HISTORICAL NOTE: Promulgated by the Department of Health and Hospitals, Board of Pharmacy, LR 14:708 (October 1988), effective January 1, 1989, amended LR 29:2105 (October 2003), effective January 1, 2004, amended LR 39:

§2535. General Standards

A. - C. ...

D. - D.3. Repealed

E. ..

F. Labeling of Compounded Products.

1. ...

2. - 2.i. Repealed

G. Manufacturing Activities. No pharmacy shall engage in the manufacturing of drugs or drug products within the prescription department.

AUTHORITY NOTE: Promulgated in accordance with R.S. 37:1182

HISTORICAL NOTE: Promulgated by the Department of Health and Hospitals, Board of Pharmacy, LR 14:708 (October 1988), effective January 1, 1989, amended LR 23:1316 (October 1997), amended LR 29:2105 (October 2003), effective January 1, 2004, amended LR 39:

§2537. Requirements for Compounding of Sterile Products

A. - F.

G. Labeling.

1 a. - i. Repealed

2.

AUTHORITY NOTE: Promulgated in accordance with R.S. 37:1182.

HISTORICAL NOTE: Promulgated by the Department of Health and Hospitals, Board of Pharmacy, LR 14:708 (October 1988), effective January 1, 1989, amended LR 29:2106 (October 2003), effective January 1, 2004, amended LR 39:

Malcolm J. Broussard Executive Director

1301#007